- Research Article
- 10.1016/j.annonc.2025.05.275
260MO AGITG ASCEND study: Randomised, double-blind phase II study of certepetide (CERT) or placebo (PLA) added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC): Cohort B progression-free survival (PFS) results
- Jul 01, 2025
- Annals of Oncology
- A Dean + 19 more +19
